Amgen, Inc.

When clinical trial details are teased but deferred, investors will take a steer from the company management and key opinion leader commentaries. This has the potential for bias. Recent events around

Data presented in two oral sessions at the American Society of Clinical Oncology on the PD-1 inhibitor Libtayo (cemiplimab-rwlc) and the BCMAxCD3-directed bispecific antibody linvoseltamab illustrate

Europe’s Unified Patent Court has given its first insight into how it will handle infringements of second medical use claims, after its verdict in the showdown between Sanofi/Regeneron Pharmaceuticals

While significant progress has been made in the treatment of non-small cell lung cancer (NSCLC), small-cell lung cancer (SCLC) has seen fewer advances and patients continue to have limited treatment o